7 Concordance of MET amplification detection between FISH and NGS in NSCLC

The INSIGHT-2 trial validated MET amplification as a therapeutic drug target for combination tepotinib-osimertinib in EGFR-mutated NSCLC. Its detection has traditionally relied on fluorescence in situ hybridization (FISH), but this is a separate test to next generation sequencing (NGS), with additional costs. We evaluated the relationship of MET copy number status detected by FISH or NGS to determine if FISH can be abandoned in the diagnostic workup.